Research programme: antibody therapeutics - Adimab/Takeda

Drug Profile

Research programme: antibody therapeutics - Adimab/Takeda

Alternative Names: Bispecific antibody therapeutics - Adimab/Takeda; Monoclonal antibody therapeutics - Adimab/Takeda

Latest Information Update: 29 Apr 2016

Price : $50

At a glance

  • Originator Adimab; Takeda
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 29 Apr 2016 Early research in Cancer in USA (unspecified route)
  • 26 Apr 2016 Adimab and Takeda agree to research and develop Monoclonal and Bispecific antibody therapeutics for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top